We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 14, 2020

Effect of Osimertinib and Bevacizumab on PFS of Patients With Metastatic EGFR-Mutant Lung Cancers

JAMA Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial
JAMA Oncol 2020 May 28;[EPub Ahead of Print], HA Yu, AJ Schoenfeld, A Makhnin, R Kim, H Rizvi, D Tsui, C Falcon, B Houck-Loomis, F Meng, JL Yang, Y Tobi, G Heller, L Ahn, SA Hayes, RJ Young, ME Arcila, M Berger, JE Chaft, M Ladanyi, GJ Riely, MG Kris

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading